Skip to content
10-Q

Quarterly Report

ACER THERAPEUTICS INC.

0000950170-23-042436

← back to feed
Filed
Aug 14, 2023 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2023 · Aug 1, 2023 24.46M sh
Shares Diluted Q2 2023 · Jun 30, 2023 24.46M sh
Shares Diluted Q2 2023 · Jun 30, 2023 22.77M sh
Capex Q2 2023 · Jun 30, 2023 $3.07K
Operating Cash Flow Q2 2023 · Jun 30, 2023 −$14.52M
Cash And Equivalents Q2 2023 · Jun 30, 2023 $1.55M
Cash And Equivalents Q2 2023 · Dec 31, 2022 $2.33M
Stockholders Equity Q2 2023 · Jun 30, 2023 −$33.25M
Stockholders Equity Q2 2023 · Mar 31, 2023 −$26.11M
Stockholders Equity Q2 2023 · Dec 31, 2022 −$16.76M
Current Liabilities Q2 2023 · Jun 30, 2023 $43.43M
Current Liabilities Q2 2023 · Dec 31, 2022 $18.95M
Total Liabilities Q2 2023 · Jun 30, 2023 $47.89M
Total Liabilities Q2 2023 · Dec 31, 2022 $28.39M
Current Assets Q2 2023 · Jun 30, 2023 $6.75M
Current Assets Q2 2023 · Dec 31, 2022 $3.52M
Total Assets Q2 2023 · Jun 30, 2023 $14.65M
Total Assets Q2 2023 · Dec 31, 2022 $11.62M
Eps Diluted Q2 2023 · Jun 30, 2023 −$0.33
Eps Diluted Q2 2023 · Jun 30, 2023 −$1.07
Eps Basic Q2 2023 · Jun 30, 2023 −$0.33
Eps Basic Q2 2023 · Jun 30, 2023 −$1.07
Rd Expense Q2 2023 · Jun 30, 2023 $1.44M
Rd Expense Q2 2023 · Jun 30, 2023 $3.86M
Net Income Q2 2023 · Jun 30, 2023 −$8.09M
Net Income Q2 2023 · Jun 30, 2023 −$24.37M
Net Income Q2 2023 · Mar 31, 2023 −$16.28M
Operating Income Q2 2023 · Jun 30, 2023 −$4.29M
Operating Income Q2 2023 · Jun 30, 2023 −$9.28M